Bleomycin in Vascular Malformations: The Definitive Guide

Bleomycin is a medicine that can be injected directly into certain vascular malformations to damage the abnormal vessel lining and help the lesion shrink over time.

Bleomycin is also used as a chemotherapy drug, but in sclerotherapy it is used very differently: the dose is much lower and it is injected locally into the malformation rather than given systemically for cancer treatment.

Bleomycin is mainly used for low-flow vascular malformations, especially venous malformations and lymphatic malformations, and it is often considered particularly useful in delicate areas such as the face, orbit, oral cavity, and airway.

Bleomycin is often preferred in critical head and neck areas because it usually causes less aggressive swelling than stronger sclerosants such as ethanol, which can be important near the eyes, tongue, and throat.

Bleomycin binds to DNA and causes strand breaks, which damages the target cells; when used inside a vascular malformation, this helps injure the abnormal endothelium and promotes fibrosis and lesion regression.

Published studies and reviews report meaningful clinical improvement in many patients, with reported improvement rates commonly around 69% to 96% depending on lesion type, location, and how response is measured.

The number of sessions varies because response depends on the type, size, depth, and diffuseness of the malformation; some patients improve after one treatment, while others need staged sessions spaced weeks apart.

There can be temporary pain, swelling, or discomfort after the injection, and some studies also report short-term symptoms such as headache, nausea, or mild fever.

The more common side effects are usually local and temporary, including swelling, pain, redness, skin pigmentation changes, and occasionally nausea or fever.

Yes, hyperpigmentation can occur after treatment, and it is usually a known minor side effect rather than a dangerous complication.

Pulmonary fibrosis is the best-known serious toxicity of bleomycin, but the risk is mainly associated with high cumulative systemic exposure; published low-dose sclerotherapy guidance notes that this complication has not been reported in large meta-analyses of low-flow vascular malformation sclerotherapy, although rare acute lung toxicity cases have been described.

Several sources cite higher concern for pulmonary toxicity when cumulative lifetime exposure approaches about 300,000 IU to 400 mg, which is far above the doses typically used in local sclerotherapy practice.

Extra caution is generally needed in patients with significant kidney impairment, prior high cumulative bleomycin exposure, advanced age, or other factors that may increase the risk of drug toxicity.

They are different agents with different strengths and risks, but bleomycin is often chosen when the goal is a more controlled treatment with less intense tissue injury and less dangerous swelling in sensitive anatomic areas.

Bleomycin usually works gradually rather than instantly, so improvement is often assessed over weeks to months after treatment.

Not always; many vascular malformations improve significantly, but some lesions are diffuse, complex, or recurrent and may need repeated treatment or multimodal management.

It can be used alone, and in some centers it is also combined with image guidance or adjunctive techniques such as electrosclerotherapy to improve drug uptake in selected lesions.

Patients should contact their treating doctor if they develop severe swelling, breathing difficulty, intense pain, fever that persists, skin breakdown, or any unexpected symptoms after the procedure.